GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
132.18
-2.14 (-1.59%)
At close: 4:00PM EST

132.18 0.00 (0.00%)
After hours: 4:42PM EST

Stock chart is not supported by your current browser
Previous Close134.32
Open136.93
Bid132.00 x 100
Ask145.00 x 100
Day's Range130.58 - 138.69
52 Week Range105.12 - 179.65
Volume346,200
Avg. Volume560,358
Market Cap4.275B
Beta (3Y Monthly)4.01
PE Ratio (TTM)N/A
EPS (TTM)-8.74
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est179.09
Trade prices are not sourced from all markets
  • Cannabis markets are expected to grow by 700 percent by 2020: RPT
    Yahoo Finance Video5 days ago

    Cannabis markets are expected to grow by 700 percent by 2020: RPT

    A health drink company called New Age Beverages is cashing in on the ongoing cannabis craze. Yahoo Finance’s Alexis Christoforous speaks to the CEO of New Age Beverages Brent Willis.

  • Weed is on the ballot in these 5 states
    Yahoo Finance Video8 days ago

    Weed is on the ballot in these 5 states

    Cannabis is on the ballot in several states across the U.S. tomorrow. Yahoo Finance's Alexis Keenan breaks it down for views.

  • 'Important to distinguish between what's medicine and wha...
    CNBC Videos12 days ago

    'Important to distinguish between what's medicine and wha...

    Jim Cramer hears from GW Pharmaceuticals CEO Justin Gover about his company's cannabis-based epilepsy treatment that just launched in the United States.

  • GW Pharma CEO after new drug launch: It's 'important to d...
    CNBC Videos12 days ago

    GW Pharma CEO after new drug launch: It's 'important to d...

    Jim Cramer hears from GW Pharmaceuticals CEO Justin Gover about his company's cannabis-based epilepsy treatment that just launched in the United States.

  • What to Expect from Cannabis Player Curaleaf’s Q3 Earnings
    Market Realist4 hours ago

    What to Expect from Cannabis Player Curaleaf’s Q3 Earnings

    Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. Curaleaf Holdings has announced that it will release its third-quarter earnings results on November 26. Analysts expect Curaleaf Holdings to report revenue of 31.4 million Canadian dollars in the third quarter.

  • ACCESSWIRE5 hours ago

    Election Night Cannabis Approvals Could Benefit These Companies

    HENDERSON, NV / ACCESSWIRE / November 13, 2018 / Last Tuesday's election was great news for cannabis companies. With Michigan approving recreational marijuana and several other measures passing investors ...

  • Why GW Pharmaceuticals Stock Dropped 20% in October
    Motley Fool3 days ago

    Why GW Pharmaceuticals Stock Dropped 20% in October

    This marijuana stock had a tough month last month. Here's what investors should know.

  • CNBC3 days ago

    Why people love CBD — the cannabis product that won't get you high

    The wave of marijuana legalization in recent years has more and more Americans toking up legally and experimenting with everything from candy to skincare products infused with cannabis. CBD products have become increasingly popular in recent years, as more and more producers market CBD as the new "it" drug for the health and wellness set — one that has been touted as a pain reliever and a treatment for anxiety, among other potential applications. Last year, consumer sales of CBD products topped $350 million in the United states, more than triple the amount sold in 2014, and various estimates predict the market could reach $2 billion within the next two to four years .

  • Assessing GW Pharmaceuticals’ Year-to-Date Performance
    Market Realist4 days ago

    Assessing GW Pharmaceuticals’ Year-to-Date Performance

    GW Pharmaceuticals (GWPH) is a developer of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenue of $3.46 million in the third quarter, reflecting a 10.2% year-over-year revenue rise in the quarter.

  • How Marijuana-Focused Biotech Companies Have Performed in 2018
    Market Realist4 days ago

    How Marijuana-Focused Biotech Companies Have Performed in 2018

    Exploring Marijuana-Focused Biotech Companies' 2018 PerformancesMarijuana-focused biotech companies

  • Investopedia6 days ago

    Top Marijuana Stocks to Watch

    Pot stocks are blazing hot, but before you open your wallet to get a piece of the action, here are a few things that could help you.

  • Barrons.com6 days ago

    Marijuana Stocks Are Being Bought Up by Big Banks

    Bank of Montreal owned $73 million in U.S.-listed pot stocks at the end of the third quarter. CIBC and U.S. Bancorp owned $5 million and $2 million, respectively.

  • 9 High-Risk Stocks to Buy for Massive Rewards
    InvestorPlace7 days ago

    9 High-Risk Stocks to Buy for Massive Rewards

    Teva Pharmaceutical (NYSE:TEVA) is doing a lot better this year — up just shy of 20%. Its key drug, Copaxone, which treats multiple sclerosis, is facing generic competition from Mylan (NASDAQ:MYL), among others. The company has sold assets to clean up its balance sheet, which has de-risked the story somewhat.

  • 3 Smokin’ Hot Marijuana Stocks to Trade for the Next High
    InvestorPlace7 days ago

    3 Smokin’ Hot Marijuana Stocks to Trade for the Next High

    Amid all the ruckus of 2018 an investing thesis has emerged that has taken Wall Street by storm: Marijuana stocks surged almost like bitcoin did in its heyday.

  • ACCESSWIRE7 days ago

    CBD Stocks on The Rebound

    HENDERSON, NV / ACCESSWIRE / November 6, 2018 / As the stock market plummeted early October cannabis companies stayed strong, buoyed up by legislative changes in Canada. The cannabis market appears set ...

  • GlobeNewswire7 days ago

    GW Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results and Host Conference Call on 27 November, 2018

    GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 27 November, 2018 its fourth quarter and year-end financial results for the period ending 30 September, 2018. GW will also host a conference call the same day at 4:30 p.m. EST. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

  • The First Cannabis-Derived Drug Is Now on Pharmacy Shelves
    Motley Fool9 days ago

    The First Cannabis-Derived Drug Is Now on Pharmacy Shelves

    This cannabidiol-based therapy comes with a mammoth list price of $32,500 a year.

  • GW Pharmaceuticals PLC (GWPH) Dips More Than Broader Markets: What You Should Know
    Zacks11 days ago

    GW Pharmaceuticals PLC (GWPH) Dips More Than Broader Markets: What You Should Know

    In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $145.71, marking a -1.05% move from the previous day.

  • Benzinga11 days ago

    Experts Weigh In On Medical Cannabis Products Now Available In The UK

    The global cannabis industry took two big steps forward this week. On Oct. 31, Mexico’s Supreme Court said the laws that ban recreational weed are unconstitutional, essentially opening the door for a potential legalization of pot in the future. The UK government rescheduled certain cannabis-based products for medicinal use.

  • Cannabis investor: 'It's not just about Canada. It's not just about the US'
    Yahoo Finance11 days ago

    Cannabis investor: 'It's not just about Canada. It's not just about the US'

    Investors aren't being scared off from the cannabis market, as they look to play the long game.

  • Benzinga11 days ago

    A Complete List Of NYSE And NASDAQ-Listed Cannabis Companies

    As the cannabis industry keeps pushing forward, more companies are moving to list their stock on a major U.S. exchange like the NYSE or NASDAQ. On Friday, Canadian medical marijuana producer Aphria Inc ...

  • ACCESSWIRE11 days ago

    Friday's Top Trending Marijuana Stocks

    CORAL GABLES, FL / ACCESSWIRE / November 2, 2018 / During the second half of the week, marijuana stocks rallied after weeks of downward movement. The cannabis industry was joined by Britain and other reports ...

  • TheStreet.com11 days ago

    GW Pharmaceuticals Is Poised to Rally to New Highs, Risk Defined

    GWPH has rallied up 30% for the year, including 7% Thursday on news that both the FDA and DEA will allow the company to sell its epilepsy drug in the U.S. Gover said GWPH has worked for 20 years on this drug and Thursday was a big milestone for their company. Gover explained that the FDA sets a very high bar when it comes to the safety and efficacy of the drugs they approve.

  • CNBC12 days ago

    GW Pharma CEO: It's 'important to distinguish between what's medicine and what's not' in cannabis

    In the world of cannabis, knowing what's real medicine and what isn't is essential, GW Pharmaceuticals CEO Justin Gover tells Jim Cramer. U.S. federal authorities recognize "real science," Gover says after his company's cannabis-based, FDA-approved epilepsy treatment launches in the United States. Knowing the difference between real, federally-approved medicine and alternative treatments is key when it comes to cannabis, says GW Pharmaceuticals GW2-FF CEO Justin Gover, whose company's cannabis-based epilepsy treatment launched Thursday in the United States.

  • ACCESSWIRE12 days ago

    Oversold CBD Stocks

    HENDERSON, NV / ACCESSWIRE / November 1, 2018 / Last week, Marijuana stocks saw a steep selloff as investors took profits after the big legalization event in Canada. At this point there are plenty of CBD ...